A recent study conducted by researchers at the University of Arizona has found that women with endometriosis have lower levels of anti-Müllerian hormone (AMH), which is associated with ovarian reserve, compared to women without the condition. The study, which included 1,961 premenopausal women, found that those with endometriosis had 29.6% lower AMH levels than those without. The researchers suggest that this may be one mechanism through which endometriosis influences infertility, younger age at menopause, and cardiovascular disease. Further research is needed to explore the long-term effects of endometriosis on AMH levels in the general population. [Extracted from the article]
Trovalusci, Emanuele, Rossato, Marco, Gamba, Piergiorgio, and Midrio, Paola
Abstract
To collect data on sexual and fertility issues in adult male patients with history of anorectal malformations (ARM). Thirty adult males born with ARM, cared for at the Pediatric Surgery of Treviso and Padua Hospitals, were enrolled and interviewed about sexual habits and relationships. Testicular ultrasound, evaluation of male sex hormones and semen analysis were performed to assess testicular function and compare data with 15 fertile controls. Presence of erectile dysfunction was evaluated with IIEF-5 questionnaire. Cryptorchidism and recurrent orchiepididymitis were reported in 33% and 40% of patients, respectively. Average testicular volume resulted significantly lower than fertile controls (11.1 vs 14.3 mL, p = 0.002) and 53.5% presented testicular hypotrophy (< 10 mL). Erectile dysfunction was reported by a single patient and ejaculatory anomalies by 46.5%. Thirteen patients were azoospermic/cryptozoospermic; 6 of them presented a reduced peripheral sensitivity to androgens (ASI > 139). Coital debut resulted delayed at 18 years old (vs 15 years in the control group). Overall 63.5% reported their condition did not affect their sexual sphere. Evaluation of testicular function is recommended in ARM patients to detect and treat possible infertility disorders, to recognize the clinical conditions which could affect the spermatogenesis since childhood, and to guarantee psychological support. Prognosis study. Level III (case–control study). [ABSTRACT FROM AUTHOR]
A recent report from the Department of Obstetrics and Gynecology discusses the impact of ovarian endometrioma and endometriotic cystectomy on anti-Mullerian hormone (AMH) and antral follicle count (AFC), which are measures of ovarian reserve in women with ovarian endometrioma. The report found that endometriotic cystectomy, particularly the stripping technique, negatively affects ovarian reserve in the short and long term. The damage to ovarian reserve is more pronounced in bilateral cases compared to unilateral cases. The report suggests that AMH should be the preferred biomarker for counseling and managing women with endometrioma before surgery. However, further research is needed to increase the level of evidence and address remaining questions. [Extracted from the article]
A recent report from Kasturba Medical College discusses the potential benefits of intra-ovarian injection of platelet-rich plasma (PRP) for women with poor ovarian response (POR) or premature ovarian insufficiency (POI). The study analyzed the effects of PRP on pregnancy rates, oocyte and embryo formation, and ovarian reserve markers such as antral follicular count and anti-Mullerian hormone. The findings suggest that PRP injection may have a moderate level of evidence in improving these outcomes. However, further randomized studies are needed to confirm these results. [Extracted from the article]
A recent study conducted by researchers at Korea University College of Medicine compared the impact on ovarian reserve after minimally invasive ovarian cystectomy using two platforms: the Da Vinci robotic system (Xi and SP) and the laparoscopic system. The study found that there were no significant differences in preoperative age, cyst size, estimated blood loss, hospital stay, adhesion detachment rate, and cyst rupture rate between the two groups. However, the laparoscopic group had a significantly shorter operative time. The study also found that the Da Vinci robotic system was not inferior to the laparoscopic system in preserving ovarian function. [Extracted from the article]
This document provides information about a clinical trial being conducted at the West China Second University Hospital in China. The trial aims to compare different methods of hemostasis during laparoscopic ovarian cystectomy in women with benign ovarian cysts. The study will involve 165 participants and is expected to be completed by June 2026. The eligibility criteria for participants are outlined, and the contact information for the primary investigator is provided. The document also includes keywords related to the study, such as gynecology, women's health, and clinical research. [Extracted from the article]
A study conducted at Peking Union Medical College Hospital in Beijing, China, aimed to investigate the risk factors associated with a decrease in ovarian reserve in patients with endometriomas after laparoscopic cystectomy. The study analyzed the levels of anti-Mullerian hormone (AMH) and other clinical data from 233 patients with endometriomas and 57 patients with non-endometrioma ovarian cysts. The results showed that older age, higher body mass index (BMI), and shorter menstrual cycles were associated with decreased AMH levels in patients with endometriomas. Additionally, patients with bilateral cysts, advanced surgical staging, or a completely enclosed Douglas pouch had significantly lower AMH levels. The study concluded that laparoscopic removal of endometriomas can adversely affect ovarian reserve, and it is important to conduct thorough patient evaluations and provide comprehensive patient education for appropriate fertility preservation guidance. [Extracted from the article]
A recent study conducted at Dhaka Medical College Hospital in Bangladesh explored the relationship between hypothyroidism and ovarian reserve in infertile women. The researchers found that impaired thyroid function can affect follicular growth and development, leading to a reduction in the number of follicles in the ovaries. The study also revealed a negative association between anti-thyroid antibodies and anti-Mullerian hormone, suggesting that hypothyroidism has a negative effect on ovarian reserve. These findings highlight the importance of considering thyroid function in the evaluation and treatment of infertility in women. [Extracted from the article]
A recent study conducted by researchers at Shahid Beheshti University of Medical Sciences investigated the effects of metformin on anti-Mullerian hormone (AMH) levels in women with polycystic ovarian syndrome (PCOS). The study analyzed data from 16 controlled trials involving 484 participants. The findings showed that metformin significantly reduced AMH levels in both single-arm and randomized clinical trials. The study concluded that metformin treatment has a beneficial effect on reducing AMH levels in women with PCOS. Further details of the study can be found in the BMC Endocrine Disorders journal. [Extracted from the article]
A scoping review conducted by researchers at Radboud University Nijmegen in the Netherlands explores the fertility dilemmas faced by girls with Turner Syndrome (TS), a genetic condition where individuals lack a partial or complete sex chromosome. The review highlights the importance of assessing a girl's fertility potential and providing comprehensive counseling on family planning options from an early age. The study also discusses the role of anti-Mullerian hormone (AMH) in estimating ovarian function and the increasing use of fertility preservation techniques such as oocyte vitrification and ovarian tissue cryopreservation. However, the research notes that only a minority of girls with TS receive specialized counseling on fertility, and there is a need for a reliable prognostic model to determine which girls might benefit from fertility preservation. [Extracted from the article]
A recent study conducted in Singapore focused on the impact of age and lifestyle on anti-Mullerian hormone (AMH) levels and ovarian reserve in Asian women with and without polycystic ovary syndrome (PCOS). PCOS affects 4-20% of women of reproductive age and is a common cause of infertility. The study found that elevated AMH levels are associated with PCOS, but an exact cut-off value remains elusive. The research suggests that lifestyle modifications, such as maintaining a healthy BMI and quitting smoking, may have beneficial effects for Asian women with PCOS. [Extracted from the article]
A recent study conducted at Cairo University in Egypt explored the levels of anti-Mullerian hormone (AMH) and inhibin-B in cases of non-obstructive azoospermia (NOA) and obstructive azoospermia (OA). The study found that inhibin-B levels were significantly lower in NOA cases compared to OA cases and controls. Additionally, there were positive correlations between AMH and inhibin-B, as well as between inhibin-B and free testosterone (FT) and weak correlation between beta inhibin and luteinizing hormone (LH). The study suggests that inhibin-B is expressed by Leydig cells and has correlations with FT and LH. [Extracted from the article]
A recent study conducted by researchers at the University of Paris Saclay has found that anti-Mullerian hormone (AMH) induces autophagy, a cellular process that helps preserve the pool of primordial follicles (PMFs) in mice. AMH is known for its inhibitory role in the growth of PMFs, but this study reveals its additional role in promoting their survival through autophagy activation. The researchers observed a decrease in the phosphorylation of the FOXO3A transcription factor and an increase in autophagy in mouse ovaries treated with AMH. These findings suggest that AMH protects the ovarian reserve by inhibiting follicular growth and inducing autophagy. [Extracted from the article]
A recent study conducted by researchers at the Faculty of Medicine Universitas Padjadjaran in Indonesia explored the correlation between pre-chemotherapy Anti-Mullerian Hormone (AMH) levels, menstrual status, and the prediction of ovarian function recovery in pre-menopausal women with breast cancer. The study found that there was a significant difference in AMH levels before and after six cycles of chemotherapy, with lower levels observed after treatment. Additionally, there was a high correlation between pre-chemotherapy AMH levels and menstrual status six months after treatment. The researchers concluded that AMH levels could be used to predict ovarian function recovery in these patients. [Extracted from the article]
A recent study conducted by the Instituto Nacional de Cancer in Rio de Janeiro, Brazil, explored the impact of radioiodine (RAI) treatment on the female reproductive system in patients with pediatric differentiated thyroid cancer (DTC). The study found that serum anti-Mullerian hormone (AMH) levels were lower in patients who received multiple RAI doses, particularly those who had a cumulative RAI dose above 200 mCi. The findings suggest that further research is needed to fully understand the effects of RAI on fertility, taking into account cumulative activity and treatment strategies. This information may be valuable for individuals researching thyroid cancer and its treatment options. [Extracted from the article]
A recent study conducted by researchers at the DOW University of Health Sciences in Karachi, Pakistan, has provided new insights into Persistent Mullerian Duct Syndrome (PMDS), a rare male disorder of sexual development. PMDS is characterized by the presence of female internal organs in phenotypically and genotypically male individuals due to a deficiency of anti-mullerian hormone or insensitivity of tissues to this hormone. The study presented a case report of a 19-year-old male who was diagnosed with bilateral cryptorchidism and a rudimentary uterus. The patient underwent laparoscopic surgery to remove the rudimentary uterus after a trial of stepwise orchidopexy followed by orchidectomy. This research has been peer-reviewed and published in the Journal of the Pakistan Medical Association. [Extracted from the article]
A recent study from Brigham and Women's Hospital explores the use of assisted reproductive technology (ART) in people with epilepsy. The study discusses the hormonal influences on epilepsy and catamenial epilepsy, fertility considerations for women with epilepsy, and management considerations for people with epilepsy undergoing ART. The research suggests that ART can be an effective treatment for individuals with epilepsy who want to conceive, but closer monitoring and adjustments to antiseizure medication may be necessary for optimal outcomes. However, more research is needed to better understand the impact of ART on seizure frequency and medication levels. [Extracted from the article]
A recent study conducted at Suez Canal University in Egypt compared the effects of Dienogest therapy and laparoscopic cystectomy on ovarian reserve in women with endometriomas. The study found that Dienogest therapy increased ovarian reserve, as measured by antral follicle count and serum anti-mullerian hormone, while surgical excision decreased ovarian reserve. Both treatment options resulted in a reduction in pelvic pain. The researchers concluded that Dienogest therapy can help preserve ovarian reserve in women with endometriomas. Further information on the study can be found in the Journal of Endometriosis and Pelvic Pain Disorders. [Extracted from the article]
Abstract The effect of bone marrow-derived mesenchymal stem cells on cadmium-induced liver and kidney damage was studied in Sprague Dawley rats. The study employed three animal groups: Group 1 served as control animals; Group 2 rats were dosed intra-peritoneally with 2 mg of cadmium chloride per kg body weight, and Group 3 rats were again dosed with a single intraperitoneal injection of 2 mg of cadmium chloride per kg body weight two doses of 106 cells each intravenously. Finally, the animals were killed using halothane inhalation anesthesia. Semen analysis (total sperm count, viability, motility, and % of normal sperm), biochemical estimations (serum total protein, uric acid, creatinine, levels of enzymes ALT, AST, and ALP, and levels of hormones LH, FSH, Inhibin, and testosterone), and histopathological analysis of liver and kidney tissue sections (using hematoxylene and eosin stains) were conducted. The results showed that when compared to controls, cadmium exposure drastically decreased total sperm count, viability, motility, and % of normal sperm, decreased serum total protein, increased serum uric acid and creatinine levels, increased levels of ALT, AST, and ALP enzymes, decreased levels of testosterone and inhibin, increased levels of LH and FSH, and caused significant histopathological abnormalities in both kidney and liver tissues. Treatment with stem cells ameliorated the effects of cadmium-induced toxicity significantly (p < 0.05) of the histopathological and biochemical parameters. In conclusion, the study reinforces previous findings that bone marrow mesenchymal stem cells can ameliorate the toxic effects of cadmium chloride and may be used as a potential therapeutic strategy for cadmium-induced adverse effects. Highlights • Exposure to Cd damages the testis and tubule, causing necrosis and complications. • Rats exposed to Cd experience reduced testicular damage when treated with BM-MSCs. • BM-MSCs have the capacity to repair Cd-caused testicular anomalies in mice and rats. • Tests should be conducted in animals and then humans to avoid possible poisoning. [ABSTRACT FROM AUTHOR]
A recent study conducted at Fudan University in Shanghai, China, has provided new insights into polycystic ovary syndrome (PCOS). The researchers focused on the relationship between anti-Mullerian hormone (AMH) levels and insulin resistance (IR) in adolescent girls with PCOS. They found that girls with PCOS and IR had higher levels of AMH compared to those without IR. Additionally, they identified body mass index, triglyceride levels, and AMH values as independent risk factors for IR. The study suggests that AMH may play a role in the development of IR in PCOS adolescents, and further research is needed to explore this interaction. [Extracted from the article]
A recent study from Monash University in Clayton, Australia has focused on understanding the molecular mechanisms that govern anti-Mullerian hormone (AMH) synthesis and activity. AMH has been found to play various roles, including sex determination, regulation of ovarian folliculogenesis, and measurement of ovarian reserve in fertility clinics. The researchers enhanced the processing of the AMH precursor, resulting in increased secreted AMH activity. They also identified specific residues within AMH that likely mediate receptor binding. This study provides valuable insights into the potential therapeutic applications of AMH in addressing reproductive needs. [Extracted from the article]
A recent systematic review and meta-analysis conducted by researchers at Shanghai University of Traditional Chinese Medicine evaluated the effects of ovarian injection of autologous platelet-rich plasma (aPRP) on patients with poor ovarian responder (POR). The study found that intra-ovarian injection of PRP had significant therapeutic effects in increasing levels of anti-Mullerian hormone (AMH), antral follicle count (AFC), oocyte count, and embryo count. The research suggests that this therapy may have potential in improving sex hormone levels and reproductive outcomes for patients with ovarian dysfunction. However, further rigorous trials are needed to determine the value of PRP injection in POR patients. [Extracted from the article]
A patent application by Creative Medical Technologies Inc. discusses the potential use of stem cells to treat ovarian failure. The application proposes a method that involves combining myeloid lineage cells with mesenchymal stem cells and administering the resulting microvesicles to the patient. The application suggests that this approach could be an effective treatment for ovarian failure, but further research is needed. The method aims to repair ovarian damage and reduce inflammation in the ovarian microenvironment. [Extracted from the article]
Researchers at Texas A&M University have conducted a study on granulosa cell tumors (GCTs) in the testis. The study focused on the role of transforming growth factor beta receptor 1 (TGFBR1) in the formation of GCTs. The researchers found that the activation of TGFBR1 in Sertoli cells, a type of testicular cell, led to the development of neoplasms resembling granulosa cell tumors. This study suggests that Sertoli cell reprogramming plays a key role in the development of testicular GCTs. [Extracted from the article]
A recent study conducted by researchers at Gunma University in Maebashi, Japan, explores the clinical utility of anti-Mullerian hormone (AMH) as an ovarian reserve test. The study involved a systematic review of literature and the development of expert opinions on AMH measurement. The findings of the study cover various aspects of AMH, including screening, diagnosis, evaluation, and prediction. While some clinical implications of AMH remain debatable, the expert opinions provided in this study contribute to a better understanding of AMH and its clinical significance. [Extracted from the article]
A recent study conducted in Chongqing, China examined the effects of laparoscopic surgical procedures on anti-Mullerian hormone (AMH) levels in women. The study included 162 women who underwent different procedures, including hysterectomy, oophorectomy, and fallectomy. The researchers found that all three types of surgeries had an impact on ovarian function, with oophorectomy having the most significant effect, followed by hysterectomy and then salpingo-oophorectomy. The study also found that total uterine resection had a greater impact on postoperative decline in ovarian reserve compared to subtotal uterine resection, and bilateral salpingo-oophorectomy had a greater effect than unilateral salpingo-oophorectomy. [Extracted from the article]
PRECOCIOUS puberty, ANTI-Mullerian hormone, CHINESE medicine, RESEARCH personnel, INHIBIN, TEENAGE girls, GIRLS
Abstract
A recent study conducted by researchers at Beijing University of Chinese Medicine aimed to investigate the relationship between serum levels of inhibin B (INHB) and anti-Mullerian hormone (AMH) and precocious puberty in girls. The researchers conducted a systematic review and meta-analysis of 11 studies involving 552 girls with precocious puberty and 405 healthy girls. The results showed that the level of INHB was significantly increased in girls with precocious puberty, particularly central precocious puberty (CPP) and premature thelarche (PT). However, there was no significant association between precocious puberty and the level of serum AMH. The researchers suggest that INHB levels may serve as a marker for the auxiliary diagnosis of precocious puberty, emphasizing the importance of early diagnosis and intervention to minimize the risk of physical, psychological, and social disorders in affected girls. [Extracted from the article]
Malene Lundgaard Riis, Gabriele Matilionyte, John E. Nielsen, Cecilie Melau, David Greenald, Kristine Juul Hare, Lea Langhoff Thuesen, Eva Dreisler, Kasper Aaboe, Pia Tutein Brenøe, Anna-Maria Andersson, Jakob Albrethsen, Hanne Frederiksen, Ewa Rajpert-De Meyts, Anders Juul, Rod T. Mitchell, and Anne Jørgensen
Subjects
Male, reduced androgen exposure, masculinization programming window, General Medicine, Flutamide, Testicular Hormones, Ketoconazole, ex vivo culture, Receptors, Androgen, Testis, androgen sensitivity, Androgens, Humans, Testosterone, human fetal testis
Abstract
Background Reduced androgen action during early fetal development has been suggested as the origin of reproductive disorders comprised within the testicular dysgenesis syndrome (TDS). This hypothesis has been supported by studies in rats demonstrating that normal male development and adult reproductive function depend on sufficient androgen exposure during a sensitive fetal period, called the masculinization programming window (MPW). The main aim of this study was therefore to examine the effects of manipulating androgen production during different timepoints during early human fetal testis development to identify the existence and timing of a possible window of androgen sensitivity resembling the MPW in rats. Methods The effects of experimentally reduced androgen exposure during different periods of human fetal testis development and function were examined using an established and validated human ex vivo tissue culture model. The androgen production was reduced by treatment with ketoconazole and validated by treatment with flutamide which blocks the androgen receptor. Testicular hormone production ex vivo was measured by liquid chromatography-tandem mass spectrometry or ELISA assays, and selected protein markers were assessed by immunohistochemistry. Results Ketoconazole reduced androgen production in testes from gestational weeks (GW) 7–21, which were subsequently divided into four age groups: GW 7–10, 10–12, 12–16 and 16–21. Additionally, reduced secretion of testicular hormones INSL3, AMH and Inhibin B was observed, but only in the age groups GW 7–10 and 10–12, while a decrease in the total density of germ cells and OCT4+ gonocytes was found in the GW 7–10 age group. Flutamide treatment in specimens aged GW 7–12 did not alter androgen production, but the secretion of INSL3, AMH and Inhibin B was reduced, and a reduced number of pre-spermatogonia was observed. Conclusions This study showed that reduced androgen action during early development affects the function and density of several cell types in the human fetal testis, with similar effects observed after ketoconazole and flutamide treatment. The effects were only observed within the GW 7–14 period—thereby indicating the presence of a window of androgen sensitivity in the human fetal testis.
Background: Late-onset hypogonadism is symptomatically diverse and not fully explained by circulating testosterone level. The adult testes secrete four distinct hormones (testosterone, AMH, INSL3, and InhB) into the circulation. Testosterone and InhB have proven dynamic regulation, with limited information available for AMH and INSL3. During aging, there is cellular senescence, which may underlie the diversity of hypogonadism. This leads to the postulate that the relative levels (profile) of the four testicular hormones in older men are variable and cannot be evaluated by the measurement of one hormone.Methods: 111 men aged 19-50 years and 98 men aged 70-90 years were examined. The circulating levels of the testicular hormones were measured using ELISAs, and the variation in the levels of hormones was analyzed by various correlative analyses.Results: All four hormones were largely or totally independent. Some men were deficient in multiple hormones, but no man had multiple elevated hormones. The average hormonal levels were lower in older men, with diverse profiles of the four testicular hormones. Hence, some men had one or more hormones below the reference range, with testosterone the most conserved. Consequently, testosterone levels were not indicative of the complete state of the endocrine testes.Conclusions: The four hormones vary independently of each other, in younger and older men. This indicates that they are regulated dynamically rather than influenced by endocrine cell number. Older men exhibited diverse profiles of low levels of testicular hormones, suggesting that the testes age differently between men. Testosterone alone inadequately describes gonadal states. [ABSTRACT FROM AUTHOR]
A systematic review and meta-analysis conducted by researchers at Universidade do Extremo Sul Catarinense (UNESC) in Brazil aimed to evaluate the effects of metformin treatment on Anti-Mullerian Hormone (AMH) levels in patients with polycystic ovary syndrome (PCOS). The researchers performed a search in various databases and included 16 studies in their analysis. The results showed that metformin administration in women with PCOS significantly reduced serum AMH levels. This research provides valuable insights into the potential benefits of metformin treatment for women with PCOS. [Extracted from the article]
A recent study conducted in Cameroon explored the clinical and hormonal features of puberty in children with sickle cell anemia (SCA). The study found that delayed puberty was reported in 27.3% of girls and 10% of boys with SCA. The median age of menarche was delayed by 2 years compared to healthy controls. The severity of the disease, as indicated by a history of severe infection, acute chest syndrome, and low hemoglobin levels, was associated with delayed sexual maturation in children with SCA. The researchers emphasized the importance of regular monitoring of puberty in these children. [Extracted from the article]
A recent study conducted at Children's National Hospital in Washington, D.C. explored the use of serum Anti-Mullerian Hormone (AMH) concentrations as a marker for spontaneous puberty and future fertility in Turner syndrome (TS) patients. The study found that AMH values were detectable in only 38% of patients, with higher levels observed in those with mosaic 45,X/46,XX karyotype compared to 45,X and structurally abnormal-X karyotype. Additionally, the study found that AMH levels were higher in patients with spontaneous menarche compared to those with spontaneous thelarche but no menarche. The researchers concluded that further studies in larger cohorts are needed to determine the predictive value and clinical role of AMH in the care of TS patients. [Extracted from the article]
A recent study conducted by researchers at Zhejiang University in Hangzhou, China, focused on the use of serum anti-Mullerian hormone (AMH) levels to indicate premenopausal endometrial lesions. The study included a total of 1209 patients with polycystic ovary syndrome (PCOS) and 5366 women without PCOS. The researchers found that for PCOS patients aged 20-39 years, a serum AMH level of 5.39 ng/mL was the most effective screening threshold, while for non-PCOS women in the same age group, a serum AMH value of 2.18 ng/mL was determined to be the optimal screening threshold. The study concluded that the serum AMH test and related multiple regression models could be used to warn of endometrial proliferative lesions in both PCOS and non-PCOS women aged 20-39 years. [Extracted from the article]
ANTI-Mullerian hormone, OVARIAN follicle, BREAST cancer, MEDICAL research personnel, CANCER patients
Abstract
Keywords: Amenorrhea; Anti-Mullerian Hormone; Breast Cancer; Cancer; Chemotherapy; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Gonadal Hormones; Gynecology; Health and Medicine; Hormones; Inhibins; Oncology; Testicular Hormones; Women's Health EN Amenorrhea Anti-Mullerian Hormone Breast Cancer Cancer Chemotherapy Clinical Research Clinical Trials and Studies Drugs and Therapies Gonadal Hormones Gynecology Health and Medicine Hormones Inhibins Oncology Testicular Hormones Women's Health 351 351 1 11/06/23 20231107 NES 231107 2023 NOV 7 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Researchers detail new data in breast cancer. Amenorrhea, Anti-Mullerian Hormone, Breast Cancer, Cancer, Chemotherapy, Clinical Research, Clinical Trials and Studies, Drugs and Therapies, Gonadal Hormones, Gynecology, Health and Medicine, Hormones, Inhibins, Oncology, Testicular Hormones, Women's Health. [Extracted from the article]
Anti-Mullerian Hormone, Cancer, Gynecology, Halogens, Health and Medicine, Hormones, Iodine, Oncology, Testicular Hormones, Thyroid Cancer, Thyroid Neoplasms, Women's Health Keywords: Anti-Mullerian Hormone; Cancer; Gynecology; Halogens; Health and Medicine; Hormones; Iodine; Oncology; Testicular Hormones; Thyroid Cancer; Thyroid Neoplasms; Women's Health EN Anti-Mullerian Hormone Cancer Gynecology Halogens Health and Medicine Hormones Iodine Oncology Testicular Hormones Thyroid Cancer Thyroid Neoplasms Women's Health 273 273 1 10/09/23 20231010 NES 231010 2023 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- New study results on thyroid cancer have been published. [Extracted from the article]
High anti-Mullerian hormone (AMH) levels may play a role in HG etiopathogenesis, especially in pregnant women with low progesterone levels." Keywords: Anti-Mullerian Hormone; Corpus Luteum Hormones; Gonadal Hormones; Health and Medicine; Hormones; Hyperemesis Gravidarum; Morning Sickness; Pregnancy Complications; Progesterone; Progesterone Congeners; Testicular Hormones; Therapy; Women's Health EN Anti-Mullerian Hormone Corpus Luteum Hormones Gonadal Hormones Health and Medicine Hormones Hyperemesis Gravidarum Morning Sickness Pregnancy Complications Progesterone Progesterone Congeners Testicular Hormones Therapy Women's Health 86 86 1 10/03/23 20231006 NES 231006 2023 OCT 5 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on hyperemesis gravidarum is the subject of a new report. [Extracted from the article]
Keywords: Anti-Mullerian Hormone; Clinical Research; Clinical Trials and Studies; Germ Cells; Gynecology; Health and Medicine; Oocytes; Ovum; Platelet-Rich Plasma; Testicular Hormones; Women's Health EN Anti-Mullerian Hormone Clinical Research Clinical Trials and Studies Germ Cells Gynecology Health and Medicine Oocytes Ovum Platelet-Rich Plasma Testicular Hormones Women's Health 188 188 1 09/25/23 20230926 NES 230926 2023 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New study results on testicular hormones have been published. Anti-Mullerian Hormone, Clinical Research, Clinical Trials and Studies, Germ Cells, Gynecology, Health and Medicine, Oocytes, Ovum, Platelet-Rich Plasma, Testicular Hormones, Women's Health. [Extracted from the article]
Keywords: Istanbul; Turkey; Eurasia; Anti-Mullerian Hormone; Arthritis; Autoimmune Diseases and Conditions; Drugs and Therapies; Estradiol Congeners; Gonadal Hormones; Gynecology; Health and Medicine; Hormones; Joint Diseases and Conditions; Juvenile Rheumatoid Arthritis; Musculoskeletal Diseases and Conditions; Pediatrics; Testicular Hormones; Women's Health EN Istanbul Turkey Eurasia Anti-Mullerian Hormone Arthritis Autoimmune Diseases and Conditions Drugs and Therapies Estradiol Congeners Gonadal Hormones Gynecology Health and Medicine Hormones Joint Diseases and Conditions Juvenile Rheumatoid Arthritis Musculoskeletal Diseases and Conditions Pediatrics Testicular Hormones Women's Health 305 305 1 09/11/23 20230916 NES 230916 2023 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Autoimmune Diseases and Conditions - Juvenile Rheumatoid Arthritis is the subject of a report. Istanbul, Turkey, Eurasia, Anti-Mullerian Hormone, Arthritis, Autoimmune Diseases and Conditions, Drugs and Therapies, Estradiol Congeners, Gonadal Hormones, Gynecology, Health and Medicine, Hormones, Joint Diseases and Conditions, Juvenile Rheumatoid Arthritis, Musculoskeletal Diseases and Conditions, Pediatrics, Women's Health, Testicular Hormones. [Extracted from the article]
Nigeria, Africa, Gonadal Hormones, Protein Expression, Proteomics, Testicular Hormones, Port Harcourt Keywords: Port Harcourt; Nigeria; Africa; Gonadal Hormones; Protein Expression; Proteomics; Testicular Hormones EN Port Harcourt Nigeria Africa Gonadal Hormones Protein Expression Proteomics Testicular Hormones 2681 2681 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Hormones - Gonadal Hormones have been published. [Extracted from the article]
The "egg timer" test, known clinically as the anti-Mullerian hormone (AMH) test, measures the level of anti-Mullerian hormone in the blood. Keywords: Advertising; Anti-Mullerian Hormone; Marketing; Risk and Prevention; Testicular Hormones; University of Sydney EN Advertising Anti-Mullerian Hormone Marketing Risk and Prevention Testicular Hormones University of Sydney 3283 3283 1 09/04/23 20230905 NES 230905 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- The findings are concerning to the researchers, as women may rely on website information to decide whether to have the test. [Extracted from the article]
OBJETIVO: examinar a hipótese de que o nível sérico do hormônio anti-Mülleriano (HAM) reflete o status folicular ovariano. MÉTODOS: Desenho: estudo prospectivo. Pacientes: foram incluídas 101 candidatas à FIV-TE submetidas à estimulação ovariana controlada com agonista de GnRH e FSH. Depois de atingir a supressão da hipófise e antes da administração de FSH (dia basal), os níveis séricos de HAM, inibina B e FSH foram avaliados. O número de folículos antrais foi determinado pela ultra-sonografia (dia basal) (folículo antral precoce; 3-10 mm). RESULTADOS: as médias do nível sérico de HAM, inhibina B, E2, P4 e FSH (dia basal) foram 3,4±0,14 ng/mL, 89±4,8 pg/mL, 34±2,7 pg/mL, 0,22±0,23 ng/mL e 6,6±0,1 mUI/mL, respectivamente, e a média do número de folículos antrais precoces foi 17±0,39. O nível sérico do HAM foi negativamente correlacionado com a idade (r= -0,19, pPURPOSE: to examine the hypothesis that serum anti-Müllerian hormone (AMH) levels reflect the ovarian follicular status. METHODS: Design: prospective study. Patients: we studied 101 IVF-ET candidates undergoing controlled ovarian hyperstimulation with GnRH agonist and FSH. After the achievement of pituitary suppression and before FSH administration (baseline), serum AMH, inhibin B, and FSH levels were measured. The number of antral follicles was determined by ultrasound at baseline (early antral follicles; 3-10 mm). RESULTS: at baseline, median serum levels of AMH, inhibin B, E2, P4 and FSH were 3.42±0.14 ng/mL, 89±4.8 pg/mL, 34±2.7 pg/mL, 0.22±0.23 ng/mL and 6.6±0.1 mIU/mL, respectively, and the mean number of early antral follicles was 17±0.39. Serum levels of AMH were negatively correlated with age (r=-0.19, p
Hijazi, Muhammad Mazhar, Ahmed, Muhammad Rashid, Ul Haq, Hafiz Syed Imran, Naqvi, Syed Naeemul Hassan, and Parveen, Rehana
Subjects
*MORPHOLOGY, *ALBINISM
Abstract
Withdrawal effects of chronic androgenic anabolic steroid on hormonal and testicular morphology were studied. Forty five male albino rats were divided into 1) Control 2) Chronic group and 3) Withdrawal group. Testoviron was injected at a dose of 400mg/kg body weight intramuscularly once in two weeks for 14 weeks, and then drug was withdrawan for another 14 weeks. Testes were removed and fixed in 10% formalin and processed. Following withdrawal of AAS, testicular and relative testicular weight was restored to control. Increased tubular count also returned near to normal while decreased diameter of seminiferous tubules, thickness of germinal epithelium, count and diameter of leydig cells were also restored near to normal in withdrawal group when compared with the chronically treated group. Histological observations also revealed that degenerated spermatogenic cells were returned to their normal appearance and oedematous vacuoles were reduced. Moreover, decreased level of reproductive hormones, i.e. FSH, LH and testosterone also returned to control level in withdrawal group. These results indicated that chronic AAS has substantial harmful effects on hormonal and testicular morphology. However, these adverse effects gradually restored to normal following withdrawal from AAS. [ABSTRACT FROM AUTHOR]
Anti-Mullerian Hormone, Cystic Fibrosis, Digestive System Diseases and Conditions, Gynecology, Health and Medicine, Lung Diseases and Conditions, Pancreatic Diseases and Conditions, Respiratory Tract Diseases and Conditions, Testicular Hormones, Women's Health Keywords: Anti-Mullerian Hormone; Cystic Fibrosis; Digestive System Diseases and Conditions; Gynecology; Health and Medicine; Lung Diseases and Conditions; Pancreatic Diseases and Conditions; Respiratory Tract Diseases and Conditions; Testicular Hormones; Women's Health EN Anti-Mullerian Hormone Cystic Fibrosis Digestive System Diseases and Conditions Gynecology Health and Medicine Lung Diseases and Conditions Pancreatic Diseases and Conditions Respiratory Tract Diseases and Conditions Testicular Hormones Women's Health 272 272 1 08/14/23 20230815 NES 230815 2023 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on cystic fibrosis have been presented. [Extracted from the article]
Keywords: Oulu; Finland; Europe; Anti-Mullerian Hormone; Diagnostics and Screening; Endocrine System Diseases and Conditions; Epidemiology; Health and Medicine; Ovarian Diseases and Conditions; Polycystic Ovary Syndrome; Syndromes; Testicular Hormones; Women's Health EN Oulu Finland Europe Anti-Mullerian Hormone Diagnostics and Screening Endocrine System Diseases and Conditions Epidemiology Health and Medicine Ovarian Diseases and Conditions Polycystic Ovary Syndrome Syndromes Testicular Hormones Women's Health 297 297 1 07/31/23 20230801 NES 230801 2023 AUG 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Endocrine System Diseases and Conditions - Polycystic Ovary Syndrome. Keywords for this news article include: Oulu, Finland, Europe, Anti-Mullerian Hormone, Diagnostics and Screening, Endocrine System Diseases and Conditions, Epidemiology, Health and Medicine, Ovarian Diseases and Conditions, Polycystic Ovary Syndrome, Syndromes, Testicular Hormones, Women's Health, University of Oulu. [Extracted from the article]
While AMHR2 had long been assumed to be expressed by cancer cells, we found that instead cancer-associated mesothelial cells are the tumor cell types that carry this receptor, and that ovarian cancer cells produce its ligand, AMH. In this study, we show how cancer cell reprogram these mesothelial cells into cancer-associated-mesothelial cell, which then promote the growth of the tumor. [Extracted from the article]
Anti-Mullerian Hormone, Cystectomy, Endometrioma, Endometriosis, Gynecology, Health and Medicine, Surgery, Testicular Hormones, Urologic Surgical Procedures, Women's Health Keywords: Anti-Mullerian Hormone; Cystectomy; Endometrioma; Endometriosis; Gynecology; Health and Medicine; Surgery; Testicular Hormones; Urologic Surgical Procedures; Women's Health EN Anti-Mullerian Hormone Cystectomy Endometrioma Endometriosis Gynecology Health and Medicine Surgery Testicular Hormones Urologic Surgical Procedures Women's Health 803 803 1 07/17/23 20230717 NES 230717 2023 JUL 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on endometrioma have been presented. [Extracted from the article]
However, serum anti-Mullerian hormone level does not always reflect the number of primordial follicles after chemotherapy, and chemotherapy more significantly affects primary and secondary follicles than primordial follicles." Keywords: Hyogo; Japan; Asia; Anti-Mullerian Hormone; Cancer; Chemotherapy; Drugs and Therapies; Gynecology; Health and Medicine; Hormones; Oncology; Testicular Hormones; Women's Health EN Hyogo Japan Asia Anti-Mullerian Hormone Cancer Chemotherapy Drugs and Therapies Gynecology Health and Medicine Hormones Oncology Testicular Hormones Women's Health 111 111 1 07/17/23 20230717 NES 230717 2023 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Cancer are discussed in a new report. [Extracted from the article]
Keywords: Anti-Mullerian Hormone; Assisted Reproductive Techniques; Gynecology; Health and Medicine; Testicular Hormones; Women's Health EN Anti-Mullerian Hormone Assisted Reproductive Techniques Gynecology Health and Medicine Testicular Hormones Women's Health 159 159 1 07/10/23 20230711 NES 230711 2023 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on testicular hormones. Anti-Mullerian Hormone, Assisted Reproductive Techniques, Gynecology, Health and Medicine, Testicular Hormones, Women's Health. [Extracted from the article]